Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 May 23:63:385-391.
doi: 10.2340/1651-226X.2024.34791.

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

Kjetil Taskén  1 , Soemeya F Haj Mohammad #  2 , Gro Live Fagereng #  3 , Ragnhild Sørum Falk  4 , Åslaug Helland  5 , Sahar Barjesteh van Waalwijk van Doorn-Khosrovani  6 , Katarina Steen Carlsson  7 , Bettina Ryll  8 , Katriina Jalkanen  9 , Anders Edsjö  10 , Hege G Russnes  11 , Ulrik Lassen  12 , Ebba Hallersjö Hult  13 , Iwona Lugowska  14 , Jean-Yves Blay  15 , Loic Verlingue  16 , Edvard Abel  17 , Maeve A Lowery  18 , Matthew G Krebs  19 , Kristoffer Staal Rohrberg  20 , Kristiina Ojamaa  21 , Julio Oliveira  22 , Henk M W Verheul  23 , Emile E Voest  24 , Hans Gelderblom  25 ; PRIME-ROSE Consortium and the PCM4EU Consortium
Collaborators, Affiliations

PCM4EU and PRIME-ROSE: Collaboration for implementation of precision cancer medicine in Europe

Kjetil Taskén et al. Acta Oncol. .

Abstract

Background: In the two European Union (EU)-funded projects, PCM4EU (Personalized Cancer Medicine for all EU citizens) and PRIME-ROSE (Precision Cancer Medicine Repurposing System Using Pragmatic Clinical Trials), we aim to facilitate implementation of precision cancer medicine (PCM) in Europe by leveraging the experience from ongoing national initiatives that have already been particularly successful.

Patients and methods: PCM4EU and PRIME-ROSE gather 17 and 24 partners, respectively, from 19 European countries. The projects are based on a network of Drug Rediscovery Protocol (DRUP)-like clinical trials that are currently ongoing or soon to start in 11 different countries, and with more trials expected to be established soon. The main aims of both the projects are to improve implementation pathways from molecular diagnostics to treatment, and reimbursement of diagnostics and tumour-tailored therapies to provide examples of best practices for PCM in Europe.

Results: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024.

Conclusion: PCM4EU and PRIME-ROSE were launched in January and July 2023, respectively. Educational materials, including a podcast series, are already available from the PCM4EU website (http://www.pcm4eu.eu). The first reports, including an overview of requirements for the reimbursement systems in participating countries and a guide on patient involvement, are expected to be published in 2024.

Conclusion: European collaboration can facilitate the implementation of PCM and thereby provide affordable and equitable access to precision diagnostics and matched therapies for more patients.

PubMed Disclaimer

Conflict of interest statement

The authors report there are no competing interests to declare.

Figures

Figure 1
Figure 1
Overview of the planned work-packages. (A) Work packages in PCM4EU. H. Gelderblom (PCM4EU coordinator) is leading WP1, A. Edsjö and H. Russnes are leading WP2, U. Lassen and Å. Helland are leading WP3, E. Hult and K. Taskén are leading WP4, B. Ryll and U. Lassen are leading WP5, and I. Lugowska and J.Y. Blay are leading WP6. (B) Work packages in PRIME-ROSE. H. Gelderblom is leading WP1, R. Falk is leading WP2, Å. Helland is leading WP3, S.B van Waalwijk van Doorn-Khosrovani is leading WP4, K. Carlsson is leading WP5, B. Ryll is leading WP6, K. Taskén (PRIME-ROSE coordinator) is leading WP7, K. Jalkanen is leading WP8 whereas Charlotte J. Haug is the independent ethics review in WP9.
Figure 2
Figure 2
Overview of all ongoing and soon-to-start DRUP-like trials in Europe. (A) DRUP in the Netherlands, PIs E.E Voest, H. Gelderblom & H.M.W. Verheul, ProTarget in Denmark, PIs K.S. Rohrberg & U. Lassen. FINPROVE in Finland, PI K. Jalkanen, IMPRESS-Norway in Norway, PI Å. Helland, MOSTplus and megaMOST in France, PIs J.Y. Blay & L. Verlingue, DETERMINE in United Kingdom, PI M.G. Krebs, POP in Portugal, PI J. Oliveira, ESTOPRET in Estonia, PI K. Ojamaa, and PANTUMOR-LT in Lithuania, PI E. Baltruškevičienė. (B) Stakeholder involvement in PRIME-ROSE.
See this image and copyright information in PMC

References

    1. Hoes LR, van Berge Henegouwen JM, van der Wijngaart H, Zeverijn LJ, van der Velden DL, van de Haar Jet al. . Patients with rare cancers in the Drug Rediscovery Protocol (DRUP) benefit from genomics-guided treatment. Clin Cancer Res. 2022. Apr 1;28(7):1402–1411. 10.1158/1078-0432.CCR-21-3752 - DOI - PMC - PubMed
    1. Andre F, Filleron T, Kamal M, Mosele F, Arnedos M, Dalenc Fet al. . Genomics to select treatment for patients with metastatic breast cancer. Nature. 2022. Oct;610(7931):343–348. 10.1038/s41586-022-05068-3 - DOI - PubMed
    1. Leary A, Besse B, André F. The need for pragmatic, affordable, and practice-changing real-life clinical trials in oncology. Lancet. 2023;403(10424):406-408. 10.1016/S0140-6736(23)02199-2 - DOI - PubMed
    1. van der Velden DL, Hoes LR, van der Wijngaart H, van Berge Henegouwen JM, van Werkhoven E, Roepman Pet al. . The Drug Rediscovery protocol facilitates the expanded use of existing anticancer drugs. Nature. 2019;574(7776):127–131. 10.1038/s41586-019-1600-x - DOI - PubMed
    1. Helland Å, Russnes HG, Fagereng GL, Al-Shibli K, Andersson Y, Berg Tet al. . Improving public cancer care by implementing precision medicine in Norway: IMPRESS-Norway. J Transl Med. 2022;20(1): 317. 10.1186/s12967-022-03432-5 - DOI - PMC - PubMed

LinkOut - more resources